|
|
|
|
|
Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC, Results from the CARD Study
|
Karim Fizazi, MD, Ph.D.
In this discussion on the CARD study with Alicia Morgans, Karim Fizazi discusses the study design, rationale, treatment strategy, and quality of life endpoints from his presentation at this years ASCO Genitourinary Symposium.
|
|
|
|
|
|
|
|
|
|
|
|
Optimal Steroid Use with Abiraterone
|
Gerhardt Attard, MD, Ph.D., FRCP
Gerhardt Attard joins Charles Ryan to discuss the optimal steroid and dose to be given with abiraterone for the management of castration-resistant prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
Management of Castration-Resistant Prostate Cancer
|
Cora Sternberg MD, FACP
Cora Sternberg joins Alicia Morgans and shares highlights from the Management of castration-resistant prostate cancer session at the 2019 Advanced Prostate Cancer Consensus Conference and key takeaways from the session when thinking about managing these patients with this disease.
|
|
|
|
|
|
|
|
|
 |
|
| The Impact of Treatment Delays on Prostate Cancer During the COVID-19 Pandemic - Zach Klaassen & Chris Wallis |
| Zachary Klaassen, MD, MSc and Christopher J.D. Wallis, MD, PhD |
| Christopher Wallis and Zachary Klaassen join Alicia Morgans to discuss the management guidance released by European Urology on how to best optimize the care of prostate cancer patients during the COVID-19 pandemic. |
|
|
|
|
|
|
|
|
|
|
|
Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy
|
|
A. Oliver Sartor, MD
|
| The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED) (NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EDITOR SELECTED ABSTRACTS AND COMMENTARIES
|
|
|
|
|
| Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer - Beyond the Abstract
|
| Ronald de Wit, MD, PhD
|
| The robust outcome of CARD with a hazard ratio (HR) for radiographic progression-free survival (rPFS) 0.54 in favor of cabazitaxel allows meaningful subgroup analyses.
|
|
|
|
|
|
|
 |
|
| NCCN Metastatic Castration-Resistant Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic |
| Edward M. Schaeffer, MD, Ph.D. |
| The National Comprehensive Cancer Network released new guidelines, on April 1, 2020, directing cancer care during the COVID-19 crisis, Alicia Morgans and Edward Schaeffer address patient questions about their primary treatment concerns during this unprecedented time. |
|
|
|
|
|
|
|
|
|
|
| A Prostate Cancer Patient Journey, a Spouse's View |
| Becky McLain |
| As a partner of someone with prostate cancer, Becky McLain shares a glimpse of what it is like for her as a spouse of someone with prostate cancer and for her entire family after diagnosis. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
